Benjamin Whalley

This inventor holds 20 USPTO granted patents and 23 published patent applications, plus 6 CIPO patents and 15 EPO patents, primarily in Cannabinoid Pharmacology. Top assignees: Gw Research Limited, Jazz Pharmaceuticals Research UK Limited, Gw Pharma Limited. Active years: 2016-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Benjamin Whalley. Retrieved from https://idiyas.com/inventor/benjamin-whalley

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 (Patent Applications = 23)

% Patents Active = 100.0

CIPO Patents = 6 (Patent Applications = 13)

EPO Patents = 15 (Patent Applications = 33)

Average Co-Inventor Count = 4.6

ph-index = 11

Forward Citations = 354(Granted Patents)

Location History:

Reading, GB (2016)
London, GB (2020 - 2023)
Cambridge, GB (2021 - 2024)
Histon, GB (2021 - 2024)

Company Filing History:

Jazz Pharmaceuticals Research UK Limited

Otsuka Pharmaceutical Company, Limited

patents

where one patent can have more than one assignee

Years Active: 2016-2025

Loading Chart...

Areas of Expertise:

Cannabinoid Derivatives

Pharmaceutical Composition

Cannabidiol

CBDV

Anti-Epileptic Drug

Neurodegenerative Disease

Dyskinesia Treatment

Tuberous Sclerosis

7-OH-Cannabidiol

Phytocannabinoids

Parkinson's Disease

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12403136 - Cannabinoid derivatives as pharmaceutically active compounds and methods of preparation thereof (2025-09-02),

2. 12396963 - Cannabidiol-type cannabinoid compound (2025-08-26),

3. 12383512 - Cannabidiol-type cannabinoid compound (2025-08-12),

4. 12364670 - Cannabidiol-type cannabinoid compound (2025-07-22),

5. 12357586 - Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy (2025-07-15),

6. 12350253 - Use of cannabinoids in the treatment of dyskinesia associated with parkinson's disease (2025-07-08),

7. 12263139 - Use of cannabidiol in the treatment of tuberous sclerosis complex (2025-04-01),

8. 12121499 - Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) (2024-10-22),

9. 11944600 - Use of cannabinoids in the treatment of a neurodegenerative disease or disorder (2024-04-02),

10. 11865102 - Cannabidiol preparations and its uses (2024-01-09),

11. 11793770 - 7-OH-cannabidiol (7-OH-CBD) and/or 7-OH-cannabidivarin (7-OH-CBDV) for use in the treatment of epilepsy (2023-10-24),

12. 11684598 - Use of cannabinoids in the treatment of epilepsy (2023-06-27),

13. 11590087 - Cannabidiol-type cannabinoid compound (2023-02-28),

14. 11419829 - Use of cannabidiol in combination with 5-HT2B receptor agonists or amphetamines in the treatment of epilepsy (2022-08-23),

15. 11318109 - Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) (2022-05-03),

Title: **The Innovative Contributions of Benjamin Whalley**

Introduction

Benjamin Whalley, an accomplished inventor based in Cambridge, GB, has made significant strides in the realm of pharmaceutical innovations. With an impressive portfolio of 13 patents, he has dedicated his research to exploring the therapeutic potential of phytocannabinoids, particularly in the context of neurological conditions.

Latest Patents

Whalley's most recent patents highlight groundbreaking developments in pharmaceutical compositions. One notable invention is a pharmaceutical composition that integrates phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD). This formulation is aimed at treating neurological conditions characterized by central nervous system hyper-excitability, such as epilepsy. The unique aspect of this composition is its focus on safety and efficacy, as well as its composition, which may include non-cannabinoid components like terpenes and specific cannabichromene variants.

In another innovative patent, Whalley investigates the application of cannabinoids for neurodegenerative diseases. His research demonstrates that cannabinoids, specifically cannabidiolic acid (CBDA) and cannabidivarin (CBDV), exhibit neuroprotective properties in mouse models of conditions like amyotrophic lateral sclerosis (ALS). This study also reveals that combining these cannabinoids with tetrahydrocannabinol (THC) and the drug olesoxime creates a synergistic effect, enhancing treatment efficacy.

Career Highlights

Throughout his career, Benjamin Whalley has contributed to esteemed organizations, including GW Research Limited and GW Pharma Limited. His work in these companies has been pivotal in advancing cannabinoid research and its applications in medicine, reflecting a commitment to addressing complex medical challenges through innovation.

Collaborations

Whalley's innovative journey has been enriched by collaborations with prominent colleagues such as Gary Stephens and Claire Williams. Together, they have fostered a collaborative environment focused on enhancing the understanding and application of cannabinoid therapies, which has likely contributed to the success of his inventions.

Conclusion

Benjamin Whalley's contributions to the field of pharmaceutical compositions and cannabinoid research mark him as a significant inventor. His latest patents reflect his dedication to developing safe and effective treatments for neurological disorders. As the landscape of cannabinoid therapy continues to evolve, his work stands as a testament to the ongoing innovation within this critical area of medicine.

Profile summary based on public USPTO records.